GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · IEX Real-Time Price · USD
3.700
-0.170 (-4.39%)
Apr 19, 2024, 10:02 AM EDT - Market open
GT Biopharma Stock Forecast
GTBP's stock price has decreased by -69.66% in the past year and price targets may not have had time to catch up.
Stock Price Forecast
The 2 analysts with 12-month price forecasts for GT Biopharma stock have an average target of 105, with a low estimate of 60 and a high estimate of 150. The average target predicts an increase of 2,737.84% from the current stock price of 3.70.
Analyst Consensus: Buy
* Price targets were last updated on Aug 8, 2023.
Analyst Ratings
The average analyst rating for GT Biopharma stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +3,954.05% | Aug 8, 2023 |
| EF Hutton | EF Hutton | Hold Reiterates $60 | Hold | Reiterates | $60 | +1,521.62% | Aug 7, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +3,954.05% | Jun 5, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $150 | Strong Buy | Reiterates | $150 | +3,954.05% | May 17, 2023 |
| EF Hutton | EF Hutton | Hold Reiterates $60 | Hold | Reiterates | $60 | +1,521.62% | May 16, 2023 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-11.02
from -5.64
EPS Next Year
-0.72
from -11.02
Revenue Forecast
| Revenue | 2024 | 2025 |
|---|---|---|
| High | n/a | n/a |
| Avg | n/a | n/a |
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
EPS Forecast
| EPS | 2024 | 2025 |
|---|---|---|
| High | -11.34 | -0.75 |
| Avg | -11.02 | -0.72 |
| Low | -10.58 | -0.70 |
EPS Growth
| EPS Growth | 2024 | 2025 |
|---|---|---|
| High | - | - |
| Avg | - | - |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.